(NASDAQ: RPRX) Royalty Pharma's forecast annual revenue growth rate of 14.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 8.82%.
Royalty Pharma's revenue in 2024 is $2,237,626,000.On average, 2 Wall Street analysts forecast RPRX's revenue for 2024 to be $1,628,925,482,512, with the lowest RPRX revenue forecast at $1,625,642,466,505, and the highest RPRX revenue forecast at $1,632,208,498,519. On average, 2 Wall Street analysts forecast RPRX's revenue for 2025 to be $1,739,552,202,291, with the lowest RPRX revenue forecast at $1,712,835,858,366, and the highest RPRX revenue forecast at $1,766,268,546,215.
In 2026, RPRX is forecast to generate $1,839,227,226,952 in revenue, with the lowest revenue forecast at $1,776,893,838,801 and the highest revenue forecast at $1,901,560,615,103.